ClinicalTrials.Veeva

Menu

Investigating Effects in Intestinal Permeability of Rich in Beta-glucans Pleurotus Eryngii Mushrooms Fermentation Supernatants: an Ex-vivo Study (FUNglucan)

Ö

Örebro University, Sweden

Status

Completed

Conditions

Healthy

Treatments

Other: Fermented product of Pleurotus eryngii mushroom

Study type

Interventional

Funder types

Other

Identifiers

NCT05446610
T1EDK-03404

Details and patient eligibility

About

The aim of the present study was to investigate the ability of Pleurotus eryngii mushrooms fermentation products (FS) to counteract induced intestinal hyperpermeability in human colonic tissues in an ex vivo system.

Full description

Collection of colon biopsies through sigmoidoscopy procedure will take place and the collected biopsies will be mounted in Ussing Chambers. Already collected fermentation supernatants will be added to the mucosal side of the biopsy together with a stressor and two permeability markers, in order to investigate the effects of the fibre fractions on both paracellular and transcellular permeability.

Enrollment

10 patients

Sex

All

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. Signed consent prior to any study related procedures
  2. Age 18-65 years
  3. Willing to abstain from regular consumption of prebiotics/probiotics products or medication known to alter gastrointestinal functions at least 4 weeks prior to the study visits

Exclusion criteria

  1. Previous complicated gastrointestinal surgery
  2. Presence of gastrointestinal disorder or any disorder which the principal investigator considers to affect the results of the study
  3. Current diagnosis of psychiatric disease
  4. Current and past diagnosis inflammatory gastrointestinal disease (e.g. Irritable Bowel Disease)
  5. Systemic use of antibiotics or steroids medications in the last 3 months
  6. Frequent use of NSAID (Non Steroidal Anti Inflammatory Drugs) the last 2 months prior to study visits
  7. Regular consumption of prebiotic/probiotic products for the past 4 weeks
  8. Abuse of alcohol or drugs
  9. Frequent use of laxatives, anti-diarrheal, anti-cholinergic within last 12 weeks prior to study visits
  10. Pregnancy and breast-feeding

Trial design

Primary purpose

Basic Science

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

10 participants in 1 patient group

Gut barrier function treatments
Experimental group
Description:
Stressor, fibre, combination of treatments.
Treatment:
Other: Fermented product of Pleurotus eryngii mushroom

Trial documents
1

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems